ETHICON’s Biopatch has been included in the NHS Catalogue of Potential Innovations.
This confirms that the product supports the fundamental domains of the committee by preventing people from dying prematurely, helping patients to recover from episodes of illhealth, ensuring a positive experience of care and protecting patients from avoidable harm. Biopatch, an antimicrobial dressing with Chlorhexidine Gluconate (CHG), helps to reduce local infections, catheterrelated blood stream infections (CRBSI), and skin colonisation of microorganisms commonly related to CRBSI, in patients with central venous or arterial catheters. The catalogue notes that Biopatch reduces CRBSIs by up to 69% and is proven to kill the most common pathogens such as MRSA and MSSA. “Some hospitals are saving hundreds of thousands of pounds, simply by reducing their CRBSI rates with the implementation of Biopatch as part of their bundle of care,” commented Andrew Cleworth, business manager Biopatch UK, Ireland, Nordics.
